CA2685167A1 - Methode et appareil de traitement et de controle de donnes dans un systeme de communications medicales - Google Patents
Methode et appareil de traitement et de controle de donnes dans un systeme de communications medicales Download PDFInfo
- Publication number
- CA2685167A1 CA2685167A1 CA002685167A CA2685167A CA2685167A1 CA 2685167 A1 CA2685167 A1 CA 2685167A1 CA 002685167 A CA002685167 A CA 002685167A CA 2685167 A CA2685167 A CA 2685167A CA 2685167 A1 CA2685167 A1 CA 2685167A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- sensitivity
- sensor
- value
- analyte sensor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 195
- 238000012545 processing Methods 0.000 title claims abstract description 170
- 230000006854 communication Effects 0.000 title claims abstract description 119
- 238000004891 communication Methods 0.000 title claims abstract description 119
- 239000012491 analyte Substances 0.000 claims abstract description 563
- 230000035945 sensitivity Effects 0.000 claims abstract description 390
- 230000002411 adverse Effects 0.000 claims abstract description 14
- 238000005070 sampling Methods 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 430
- 239000008103 glucose Substances 0.000 claims description 430
- 230000008859 change Effects 0.000 claims description 129
- 239000008280 blood Substances 0.000 claims description 94
- 210000004369 blood Anatomy 0.000 claims description 94
- 238000001727 in vivo Methods 0.000 claims description 60
- 238000012544 monitoring process Methods 0.000 claims description 59
- 239000002131 composite material Substances 0.000 claims description 46
- 230000005540 biological transmission Effects 0.000 claims description 41
- 238000012795 verification Methods 0.000 claims description 32
- 238000012806 monitoring device Methods 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 19
- 238000005259 measurement Methods 0.000 claims description 17
- 238000013524 data verification Methods 0.000 claims description 15
- 230000000007 visual effect Effects 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 11
- 230000002085 persistent effect Effects 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 9
- 238000013500 data storage Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000002123 temporal effect Effects 0.000 claims description 5
- 238000013496 data integrity verification Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000001514 detection method Methods 0.000 description 27
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 230000006870 function Effects 0.000 description 19
- 238000013459 approach Methods 0.000 description 13
- 238000007726 management method Methods 0.000 description 13
- 230000007704 transition Effects 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000009529 body temperature measurement Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000007175 bidirectional communication Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000027036 Hippa Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013502 data validation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012774 insulation material Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/002—Monitoring the patient using a local or closed circuit, e.g. in a room or building
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0266—Operational features for monitoring or limiting apparatus function
- A61B2560/0276—Determining malfunction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Computer Networks & Wireless Communication (AREA)
- Emergency Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91779807P | 2007-05-14 | 2007-05-14 | |
US91785907P | 2007-05-14 | 2007-05-14 | |
US91786507P | 2007-05-14 | 2007-05-14 | |
US91783707P | 2007-05-14 | 2007-05-14 | |
US91785007P | 2007-05-14 | 2007-05-14 | |
US91785607P | 2007-05-14 | 2007-05-14 | |
US91787707P | 2007-05-14 | 2007-05-14 | |
US91788907P | 2007-05-14 | 2007-05-14 | |
US91788307P | 2007-05-14 | 2007-05-14 | |
US91787307P | 2007-05-14 | 2007-05-14 | |
US60/917,865 | 2007-05-14 | ||
US60/917,889 | 2007-05-14 | ||
US60/917,859 | 2007-05-14 | ||
US60/917,883 | 2007-05-14 | ||
US60/917,850 | 2007-05-14 | ||
US60/917,798 | 2007-05-14 | ||
US60/917,873 | 2007-05-14 | ||
US60/917,837 | 2007-05-14 | ||
US60/917,877 | 2007-05-14 | ||
US60/917,856 | 2007-05-14 | ||
PCT/US2008/006247 WO2008143943A1 (fr) | 2007-05-14 | 2008-05-14 | Procédé et appareil de traitement et de contrôle de données dans un système de communication médical |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2685167A1 true CA2685167A1 (fr) | 2008-11-27 |
Family
ID=40122052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002685167A Abandoned CA2685167A1 (fr) | 2007-05-14 | 2008-05-14 | Methode et appareil de traitement et de controle de donnes dans un systeme de communications medicales |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2156684A4 (fr) |
CA (1) | CA2685167A1 (fr) |
WO (1) | WO2008143943A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210263147A1 (en) * | 2018-07-19 | 2021-08-26 | Arbe Robotics Ltd. | Apparatus And Method Of RF Built In Self-Test (RFBIST) In A Radar System |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
CA2556331A1 (fr) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Procede et systeme de communication de donnees dans un systeme de controle et de gestion de glucose en continu |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
CN102440785A (zh) | 2005-08-31 | 2012-05-09 | 弗吉尼亚大学专利基金委员会 | 传感器信号处理方法及传感器信号处理装置 |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US8135548B2 (en) | 2006-10-26 | 2012-03-13 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
WO2008130896A1 (fr) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Procédé et appareil pour réaliser le traitement et la commande de données dans un système de communication médical |
ES2784736T3 (es) | 2007-04-14 | 2020-09-30 | Abbott Diabetes Care Inc | Procedimiento y aparato para proporcionar el procesamiento y control de datos en un sistema de comunicación médica |
CA2683962C (fr) | 2007-04-14 | 2017-06-06 | Abbott Diabetes Care Inc. | Procede et appareil pour realiser le traitement et la commande de donnees dans un systeme de communication medical |
CA2683930A1 (fr) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care Inc. | Procede et appareil pour realiser le traitement et la commande de donnees dans un systeme de communication medical |
ES2817503T3 (es) | 2007-04-14 | 2021-04-07 | Abbott Diabetes Care Inc | Procedimiento y aparato para proporcionar el procesamiento y control de datos en un sistema de comunicación médica |
CA2683721C (fr) | 2007-04-14 | 2017-05-23 | Abbott Diabetes Care Inc. | Procede et appareil pour assurer une amplification de signal dynamique a etapes multiples dans un dispositif medical |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
AU2008265541B2 (en) | 2007-06-21 | 2014-07-17 | Abbott Diabetes Care, Inc. | Health management devices and methods |
WO2008157821A1 (fr) | 2007-06-21 | 2008-12-24 | Abbott Diabetes Care, Inc. | Dispositif de surveillance médicale |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US20100198034A1 (en) | 2009-02-03 | 2010-08-05 | Abbott Diabetes Care Inc. | Compact On-Body Physiological Monitoring Devices and Methods Thereof |
WO2010121084A1 (fr) | 2009-04-15 | 2010-10-21 | Abbott Diabetes Care Inc. | Système de surveillance de substances à analyser avec notification d'alertes |
EP2419015A4 (fr) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Gestion d'étalonnage de capteur d'analyte |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US20100274515A1 (en) | 2009-04-28 | 2010-10-28 | Abbott Diabetes Care Inc. | Dynamic Analyte Sensor Calibration Based On Sensor Stability Profile |
EP2425209A4 (fr) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Procédé et système pour fournir un étalonnage de détecteur d'analyte en temps réel avec remplissage rétrospectif |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
EP3689237B1 (fr) | 2009-07-23 | 2021-05-19 | Abbott Diabetes Care, Inc. | Procédé de fabrication et système de mesure d'analytes continue |
WO2011026148A1 (fr) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Système de surveillance de substance à analyser et procédés de gestion de lénergie et du bruit |
EP2473098A4 (fr) | 2009-08-31 | 2014-04-09 | Abbott Diabetes Care Inc | Dispositif et procédés de traitement de signal d'analyte |
AU2010286917B2 (en) | 2009-08-31 | 2016-03-10 | Abbott Diabetes Care Inc. | Medical devices and methods |
WO2011026053A1 (fr) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Affichages pour dispositif médical |
EP2519142B1 (fr) | 2009-12-30 | 2021-06-09 | Maquet Critical Care AB | Système et procédé pour la surveillance et la présentation en continu de substances corporelles |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
AU2012271333B2 (en) | 2011-06-17 | 2016-05-19 | Abbott Diabetes Care Inc. | Connectors for making connections between analyte sensors and other devices |
WO2013066873A1 (fr) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Dispositifs électroniques à systèmes de réinitialisation intégrés et procédés associés |
US10993646B2 (en) * | 2017-08-18 | 2021-05-04 | Abbott Diabetes Care Inc. | Systems, devices, and methods related to the individualized calibration and/or manufacturing of medical devices |
KR102082357B1 (ko) * | 2018-02-14 | 2020-02-27 | 주식회사 아이센스 | 센서 사용 정보를 이용한 생체 정보의 관리 방법 |
IL260695A (en) | 2018-07-19 | 2019-01-31 | Arbe Robotics Ltd | Method and device for eliminating waiting times in a radar system |
IL260694A (en) | 2018-07-19 | 2019-01-31 | Arbe Robotics Ltd | Method and device for two-stage signal processing in a radar system |
MY197121A (en) * | 2020-09-15 | 2023-05-26 | Abbott Diabetes Care Inc | System, apparatus, and devices for analyte monitoring |
CN117752333A (zh) * | 2022-09-19 | 2024-03-26 | 苏州百孝医疗科技有限公司 | 灵敏度确定方法、植入效果判断方法以及相关设备 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US6949816B2 (en) * | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US7027931B1 (en) * | 2000-02-24 | 2006-04-11 | Bionostics, Inc. | System for statistical analysis of quality control data |
US20040197846A1 (en) * | 2001-01-18 | 2004-10-07 | Linda Hockersmith | Determination of glucose sensitivity and a method to manipulate blood glucose concentration |
US6788965B2 (en) * | 2001-08-03 | 2004-09-07 | Sensys Medical, Inc. | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
US20040204868A1 (en) * | 2003-04-09 | 2004-10-14 | Maynard John D. | Reduction of errors in non-invasive tissue sampling |
US7651596B2 (en) * | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
-
2008
- 2008-05-14 CA CA002685167A patent/CA2685167A1/fr not_active Abandoned
- 2008-05-14 EP EP08754499A patent/EP2156684A4/fr not_active Withdrawn
- 2008-05-14 WO PCT/US2008/006247 patent/WO2008143943A1/fr active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210263147A1 (en) * | 2018-07-19 | 2021-08-26 | Arbe Robotics Ltd. | Apparatus And Method Of RF Built In Self-Test (RFBIST) In A Radar System |
US11921195B2 (en) * | 2018-07-19 | 2024-03-05 | Arbe Robotics Ltd. | Apparatus and method of RF built in self-test (RFBIST) in a radar system |
Also Published As
Publication number | Publication date |
---|---|
EP2156684A1 (fr) | 2010-02-24 |
EP2156684A4 (fr) | 2012-10-24 |
WO2008143943A1 (fr) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11300561B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US10653344B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US20210251529A1 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US10261069B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US9737249B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US10031002B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US7996158B2 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US20080287763A1 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
US20080312845A1 (en) | Method and apparatus for providing data processing and control in a medical communication system | |
CA2685167A1 (fr) | Methode et appareil de traitement et de controle de donnes dans un systeme de communications medicales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130508 |
|
FZDE | Discontinued |
Effective date: 20160516 |